Find Answers to
Common Questions

Different laboratories may use different assays, reagents and reporting standards, which can produce slightly different viral load values for the very same sample. By using the same lab each time, your results are generated by a consistent method, so they can be reliably compared from one test to the next. This makes it much easier for you and your doctor to track real trends in your HBV viral load over the course of treatment.

Viral load reflects how actively the hepatitis B virus is replicating in your body and how infectious you may be. A high viral load is generally seen in the immune-tolerant and immune-active phases, when the virus is multiplying rapidly, while a low or undetectable load is typical of the inactive carrier phase. Interpreted together with liver enzymes (SGPT/SGOT) and HBeAg status, viral load helps your doctor identify which stage of infection you are in and how closely you need to be monitored.

Measuring viral load during treatment is the most direct way to see whether the therapy is working. A steady decline shows that the virus is being suppressed, while a rising or stagnant level can signal poor response or relapse that may need a change in approach. Regular monitoring therefore guides treatment decisions and confirms progress toward a Target Not Detected result.

During pregnancy, a high maternal HBV viral load is the main factor that increases the risk of passing the infection to the baby (mother-to-child transmission). Knowing the viral load allows your doctor to assess that risk and arrange timely preventive measures, such as antiviral prophylaxis in late pregnancy and vaccination of the newborn. Careful monitoring helps protect both mother and child and greatly reduces the chance of transmission.

Untreated chronic hepatitis B can quietly progress over years to serious liver damage, including cirrhosis and liver cancer (hepatocellular carcinoma). Appropriate treatment suppresses the virus, protects liver function, and lowers the risk of these long-term complications. It also reduces the chance of transmitting the infection to others, leading to better health outcomes and quality of life.

For people living with hepatitis B, the goal is to keep the viral load as low as possible — ideally undetectable (Target Not Detected). The lower the level of HBV DNA in the blood, the less active the virus is and the lower the risk of liver damage and transmission. While exact thresholds vary by individual and treatment stage, in general lower is always better, and an undetectable result is the most reassuring outcome.

Yes. With effective treatment, the HBV viral load can fall to a level so low that the test reports "Target Not Detected," meaning the virus is no longer measurable in the blood. This indicates strong viral suppression, though continued monitoring is still important to make sure the result is maintained over time.

Yes. In clinical observations, patients on HOO-IMM PLUS-B showed a steady decline in HBV viral load, with several reaching a Target Not Detected result over the course of treatment. This polyherbal formulation works through multi-targeted action to suppress the virus while supporting healthy liver function. For guidance tailored to your individual case, we recommend a free consultation with our experts.